Mirikizumab
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Crohn Disease (CD)
Conditions
Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
Trial Timeline
Jul 16, 2025 → Feb 28, 2026
NCT ID
NCT07059130About Mirikizumab
Mirikizumab is a approved stage product being developed by Eli Lilly for Crohn Disease (CD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07059130. Target conditions include Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC).
What happened to similar drugs?
11 of 20 similar drugs in Crohn Disease (CD) were approved
Approved (11) Terminated (4) Active (9)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07446101 | Phase 1 | Recruiting |
| NCT07059130 | Approved | Recruiting |
| NCT05509777 | Phase 3 | Recruiting |
| NCT05644353 | Phase 1 | Completed |
| NCT05515601 | Phase 1 | Completed |
| NCT04548219 | Phase 1 | Completed |
| NCT04232553 | Phase 3 | Active |
| NCT04004611 | Phase 2 | Completed |
| NCT03556202 | Phase 3 | Terminated |
| NCT03519945 | Phase 3 | Active |
Competing Products
20 competing products in Crohn Disease (CD)